DDInter1340 DDInter667
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
Omeprazole {u} (Compound) palliates {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Erlotinib
Omeprazole {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Erlotinib
Omeprazole {u} (Compound) causes {v} (Side Effect) Connective tissue disorder
Connective tissue disorder {u} (Side Effect) is caused by {v} (Compound) Erlotinib
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may lead to a major life threatening interaction when taken with {v} Erlotinib
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may lead to a major life threatening interaction when taken with {v} Erlotinib
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may lead to a major life threatening interaction when taken with {v} Erlotinib
Omeprazole {u} (Compound) palliates {v} (Disease) kidney cancer
kidney cancer {u} (Disease) resembles {v} (Disease) lung cancer
lung cancer {u} (Disease) is treated by {v} (Compound) Erlotinib
Omeprazole {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Erlotinib
Omeprazole {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Erlotinib
Omeprazole {u} (Compound) binds {v} (Gene) CYP1B1
CYP1B1 {u} (Gene) is upregulated by {v} (Disease) lung cancer
lung cancer {u} (Disease) is treated by {v} (Compound) Erlotinib
Omeprazole (Compound) palliates kidney cancer (Disease) and kidney cancer (Disease) is treated by Erlotinib (Compound)
Omeprazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Erlotinib (Compound)
Omeprazole (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Erlotinib (Compound)
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may lead to a major life threatening interaction when taken with Erlotinib
Omeprazole (Compound) resembles Esomeprazole (Compound) and Es
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may lead to a major life threatening interaction when taken with Erlotinib
Omeprazole (Compound) palliates kidney cancer (Disease) and kidney cancer (Disease) resembles lung cancer (Disease) and lung cancer (Disease) is treated by Erlotinib (Compound)
Omeprazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Erlotinib
Omeprazole (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Gefitinib (Compound) and Gefitinib (Compound) resembles Erlotinib (Compound)
Omeprazole (Compound) binds CYP1B1 (Gene) and CYP1B1 (Gene) is upregulated by lung cancer (Disease) and lung cancer (Disease) is treated by Erlotinib (Compound)